Please login to the form below
formoterol
This page shows the latest formoterol news and features for those working in and with pharma, biotech and healthcare.
AZ’s COPD triple data sets up market clash with GSK
AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... In Europe it was pipped to
Latest news
-
With US approval, GSK now needs rapid uptake for COPD triple
In August, Chiesi won EU approval for its closed triple therapy Trimbow (beclometasone, formoterol and glycopyrronium), but that is administered twice-daily.
-
GSK closes in on EU approval for triple COPD therapy
The benefits of Trelegy/Elebrato - delivered using the company's Ellipta dry powder inhaler - are its ability to improve lung function compared to AstraZeneca's ICS/LABA combination Symbicort (budesonide/formoterol)
-
Smart solutions
It is not just GSK that is under pressure. The likes of AstraZeneca’s Symbicort (budesonide and formoterol), Merck &Co’s Dulera (formoterol and mometasone) and Teva’s Qvar (beclometasone) are
-
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog
picked up an approval for a three-drug combination for chronic obstructive pulmonary disorder (COPD) called Trimbow (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium).
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
More from news
Approximately 0 fully matching, plus 75 partially matching documents found.
Latest from PMHub
-
Raising Awareness: It’s World COPD Day today!
Common combinations include fluticasone proprionate/salmeterol and budesonide/formoterol, which are taken twice-daily, and fluticasone furoate/vilanterol, which is taken once-daily (5).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
Subscribe to our email news alerts
PMHub
Quintiles Medical Communications
Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
